{"filing":{"accession_number":"0001021771-26-000084","cik":"0001505497","ticker":"BRTX","company_name":"BioRestorative Therapies, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"brtx-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1505497/000102177126000084/brtx-20260529.htm"},"events":[{"id":2038,"run_id":1770,"accession_number":"0001021771-26-000084","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Lance Alstodt (President, CEO, Chairman) and Robert Kristal (CFO) entered into new employment agreements on May 27, 2026, specifying annual salaries of $600,000 and $350,000 respectively, with a three-year term through May 27, 2029.","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-05-29","items":[{"id":2591,"accession_number":"0001021771-26-000084","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on compensatory arrangements for two named executives: Lance Alstodt (President, CEO, Chairman) and Robert Kristal (CFO). Both entered into new employment agreements on May 27, 2026, specifying salary terms ($600,000 and $350,000 respectively) and a three-year term through May 27, 2029. This is a classic Item 5.02(e) disclosure of executive compensation arrangements, material to investors assessing management continuity and cost structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:05:48.736398+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":2039,"run_id":1770,"accession_number":"0001021771-26-000084","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Shareholders approved an amendment to increase authorized common shares from 75 million to 1.5 billion at a Special Meeting held on May 26, 2026, with 9,868,606 votes in favor, 2,389,059 against, and 179,207 abstentions.","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-05-29","items":[{"id":2592,"accession_number":"0001021771-26-000084","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder vote results from a Special Meeting held on May 26, 2026, reporting the votes cast for and against an amendment to increase authorized common shares from 75 million to 1.5 billion. The filing directly matches Item 5.07 (Submission of Matters to a Vote of Security Holders) and presents the vote tallies (For: 9,868,606; Against: 2,389,059; Abstentions: 179,207). A 20-fold increase in authorized shares is material to investors as it significantly expands the company's dilution capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:05:48.736398+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2591,"accession_number":"0001021771-26-000084","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on compensatory arrangements for two named executives: Lance Alstodt (President, CEO, Chairman) and Robert Kristal (CFO). Both entered into new employment agreements on May 27, 2026, specifying salary terms ($600,000 and $350,000 respectively) and a three-year term through May 27, 2029. This is a classic Item 5.02(e) disclosure of executive compensation arrangements, material to investors assessing management continuity and cost structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:05:48.736398+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-05-29"},{"id":2592,"accession_number":"0001021771-26-000084","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder vote results from a Special Meeting held on May 26, 2026, reporting the votes cast for and against an amendment to increase authorized common shares from 75 million to 1.5 billion. The filing directly matches Item 5.07 (Submission of Matters to a Vote of Security Holders) and presents the vote tallies (For: 9,868,606; Against: 2,389,059; Abstentions: 179,207). A 20-fold increase in authorized shares is material to investors as it significantly expands the company's dilution capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:05:48.736398+00:00","company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","filing_date":"2026-05-29"}]}